Arcus Biosciences/$RCUS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arcus Biosciences
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
Ticker
$RCUS
Sector
Primary listing
NYSE
Employees
601
Headquarters
Website
RCUS Metrics
BasicAdvanced
$3.7bn
-
-$3.86
0.81
-
Price and volume
Market cap
$3.7bn
Beta
0.81
52-week high
$31.74
52-week low
$8.88
Average daily volume
1.1m
Financial strength
Current ratio
3.818
Quick ratio
3.753
Long term debt to equity
48.491
Total debt to equity
51.293
Interest coverage (TTM)
-44.18%
Profitability
EBITDA (TTM)
-476
Gross margin (TTM)
-324.79%
Net profit margin (TTM)
-393.16%
Operating margin (TTM)
-415.38%
Revenue per employee (TTM)
$190,000
Management effectiveness
Return on assets (TTM)
-30.39%
Return on equity (TTM)
-90.82%
Valuation
Price to revenue (TTM)
29.236
Price to book
7.86
Price to tangible book (TTM)
7.86
Price to free cash flow (TTM)
-7.201
Free cash flow yield (TTM)
-13.89%
Free cash flow per share (TTM)
-3.988
Growth
Revenue change (TTM)
-55.34%
Earnings per share change (TTM)
25.71%
3-year revenue growth (CAGR)
-1.11%
3-year earnings per share growth (CAGR)
-0.68%
What the Analysts think about RCUS
Analyst ratings (Buy, Hold, Sell) for Arcus Biosciences stock.
RCUS Financial Performance
Revenues and expenses
RCUS Earnings Performance
Company profitability
RCUS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.